InvestoGain

Investogain Pty Limited
AFS Licence No. 334036

All correspondence to:
admin@delisted.com.au
or by mail to:
PO Box 400
Crows Nest NSW 1585

26 April 2025

Name:	OSPREY MEDICAL INC (OSP)
ISIN:	AU000000OSP4
Date of Listing:	02 May 2012
Date of Delisting:	29 August 2022

Stock Exchange Status: (updated daily)

This entity was delisted from the Australian Securities Exchange on 29 August 2022.

Legal Status: (updated monthly)

ACN: 152 854 923ABN: 97 152 854 923
Registration Date: 24 August 2011
Deregistration Date: 17 January 2023

This entity was deregistered on 17 January 2023. It has thus ceased to exist.

Capital Gains Tax (CGT) Status: (updated at least quarterly)

This entity was deregistered on 17 January 2023. Deregistration is a Capital Gains Tax Event. In our opinion you are entitled to crystallise any capital loss in the tax year that deregistration occurs providing you have not previously done so. If you did not crystallise your loss in the tax year the entity was deregistered, you may seek to re-open that year’s assessment but anyway should seek professional advice as to how best to proceed.

Updates, corrections, disagreements please email to admin@delisted.com.au

Further information: deListed and InvestoGain are operated by Investogain Pty Limited which is licensed by ASIC as an Australian Financial Services Licensee (AFSL 334036). deListed acquires only securities that it deems to be of little or no value, in circumstances where the holder is unable to sell their securities on-market in the normal manner. This service has been provided online via the company’s website www.delisted.com.au since 2004.

Getting advice: Information provided in this section is of a general nature and applicable only to Australian tax residents who hold their investments on capital account (ie for long-term investment purposes). It has been prepared without taking into account your financial needs or tax situation. Before acting on the information, deListed suggests that you consider whether it is appropriate for your circumstances and recommends that you seek independent legal, financial, or taxation advice.

Disclaimer: The information provided above is to the best of our knowledge accurate as of today. But you should bear in mind that it is of a general nature and does not constitute financial or tax advice. Investogain Pty Limited accepts no liability for any loss arising from reliance on this information, including reliance on information that is no longer current.

OSPREY MEDICAL INC(OSP)

Click here for free access to this company's:
ASX, Legal & CGT Status

Former (or subsequent) names

Shareholder links

Our website ranking of OSP:

(3 out of 5)

COMPANY WEBSITE:

OSP website

OSP contact

OSP investorRelations

OSP directors

REGISTRY:

Tower 4, 727 Collins Street Docklands VIC 3008

Tel : +61 3 9615 9800 or 61 1300 554 474
Fax : +61 2 9287 0303
RegistryWebsite RegistryEmail

Company details

ISIN: AU000000OSP4

Address: Level 13, 41 Exhibitions Street, Melbourne, Victoria, 3000
Tel: 0410 442 393 Fax: (03) 9663 6609

Date first listed: 02/05/2012
Company Secretary:
Sector: Health Care Equipment & Services Industry Group: XHJ
Activities: Development and commercialization of its proprietary CINCOR System, a medical device used for the prevention of Contrast Induced Nephropathy (CIN)

News & Events

Expand this box to read and print

company is deregistered today	17/01/2023
Strike-Off Action In Progress	30/10/2022
delisted following failure to pay the annual ASX listing fees per Listing Rule 17.15	29/08/2022
we understand the company failed to pay to ASX Limited the annual listing fees for the year ending 30 June 2023	29/08/2022
Under Listing Rule 17.6, an entity (if not already suspended) that had not paid its annual listing fees by close of business on Friday, 19 August 2022 would have its securities suspended from Official Quotation before the commencement of trading on Monday, 22 August 2022. The following entity has failed to pay to ASX Limited the annual listing fees for the year ending 30 June 2023, and each entity's securities are already suspended from quotation. Under Listing Rule 17.15, any entity that has not paid its annual listing fees as required by Listing Rule 16.5 by 5.00 pm AEST on Friday, 26 August 2022 will be removed from the Official List with effect from the close of trading on Friday, 26 August 2022.	22/08/2022
The company lodges its Quarterly Activities/Appendix 4C Cash Flow Report.	29/07/2022
The Company is working with creditors and other stakeholders to reduce the Company's debt and gain access to new sources of liquidity. Cash from ongoing operations is expected to provide sufficient liquidity to support Osprey's continuing business operations and minimise disruption to customers until completion of the restructure of Osprey's business in CY 2023. The Company expects that its shares will remain suspended from trading until at least completion of the business restructure.	01/06/2022
The company has postponed the AGM scheduled for 2 June 2022 until further notice.	26/05/2022
The company is continuing its suspension from trading in order to provide Osprey with additional time to complete its consideration of the options available to it and to provide the market with an accurate update on next steps. The suspension will continue for a period of up to 16 trading days; and the suspension will end upon the release of an announcement by Osprey in connection with its review of options.	10/05/2022
The company is reducing its workforce across all areas effective this Friday (US time). The company continues to assess next steps and expects to update the market shortly on further developments.	06/05/2022
The securities of Osprey Medical Inc. will be suspended from quotation immediately under Listing Rule 17.2, at the request of OSP, pending the release of an announcement regarding its strategic and funding options.	03/05/2022
The securities of Osprey Medical Inc (the "Company") will be reinstated to quotation immediately, following the release of an announcement by the Company. Security Code: OSP	23/03/2015
The securities of Osprey Medical Inc (the "Company") will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement by the company. Security Code: OSP	19/03/2015
listed entity carried for record purposes only	02/05/2012

company is deregistered today	17/01/2023
Strike-Off Action In Progress	30/10/2022
delisted following failure to pay the annual ASX listing fees per Listing Rule 17.15	29/08/2022
we understand the company failed to pay to ASX Limited the annual listing fees for the year ending 30 June 2023	29/08/2022
Under Listing Rule 17.6, an entity (if not already suspended) that had not paid its annual listing fees by close of business on Friday, 19 August 2022 would have its securities suspended from Official Quotation before the commencement of trading on Monday, 22 August 2022. The following entity has failed to pay to ASX Limited the annual listing fees for the year ending 30 June 2023, and each entity's securities are already suspended from quotation. Under Listing Rule 17.15, any entity that has not paid its annual listing fees as required by Listing Rule 16.5 by 5.00 pm AEST on Friday, 26 August 2022 will be removed from the Official List with effect from the close of trading on Friday, 26 August 2022.	22/08/2022
The company lodges its Quarterly Activities/Appendix 4C Cash Flow Report.	29/07/2022
The Company is working with creditors and other stakeholders to reduce the Company's debt and gain access to new sources of liquidity. Cash from ongoing operations is expected to provide sufficient liquidity to support Osprey's continuing business operations and minimise disruption to customers until completion of the restructure of Osprey's business in CY 2023. The Company expects that its shares will remain suspended from trading until at least completion of the business restructure.	01/06/2022
The company has postponed the AGM scheduled for 2 June 2022 until further notice.	26/05/2022
The company is continuing its suspension from trading in order to provide Osprey with additional time to complete its consideration of the options available to it and to provide the market with an accurate update on next steps. The suspension will continue for a period of up to 16 trading days; and the suspension will end upon the release of an announcement by Osprey in connection with its review of options.	10/05/2022
The company is reducing its workforce across all areas effective this Friday (US time). The company continues to assess next steps and expects to update the market shortly on further developments.	06/05/2022
The securities of Osprey Medical Inc. will be suspended from quotation immediately under Listing Rule 17.2, at the request of OSP, pending the release of an announcement regarding its strategic and funding options.	03/05/2022
The securities of Osprey Medical Inc (the "Company") will be reinstated to quotation immediately, following the release of an announcement by the Company. Security Code: OSP	23/03/2015
The securities of Osprey Medical Inc (the "Company") will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement by the company. Security Code: OSP	19/03/2015
listed entity carried for record purposes only	02/05/2012

Your browser may reflect a date of printing in American format.

ASX Announcements (courtesy of ASX)

Click here for free access to this company's:
ASX, Legal & CGT Status

Your comments

Please read our Terms before viewing comments.

Most recent comments

IS THE COMPANY BANKRUPT ?????

OR IT IS NOT LISTED ON STOCK EXCANGE

BUT STILL TRADING IN AMERICA ??

02/10/2024 16:07:09

Company Updates

Post your comments here

Please read our Terms before posting comments.

Click here for free access to this company's:
ASX, Legal & CGT Status

Directors' on-market share transactions (last 5)

Purchases Sales

DATE	DIRECTOR	NUMBER	PRICE	AMOUNT
04/03/2019	Neville Mitchell	185,809	$0.110 CDI	$20,362.00
06/06/2018	Neville Mitchell	250,000	$0.150 CDI	$37,500.00
15/05/2018	Neville Mitchell	250,000	$0.190 CDI	$47,500.00
17/05/2016	Neville Mitchell	100,000	$0.252 CDI	$25,180.00
16/05/2014	Neville Mitchell	50,000	$0.541 CDI	$27,061.00

Click here for the last 20 transactions all companies

Directors & Executives (current)

NAME	TITLE	DATE OF APPT
John Erb	Non Exec Chairman	02/05/2012
Mike McCormick	President, CEO	02/05/2012
Chris Nave	Non Exec Director	02/05/2012
Steven Brandt	Director	01/07/2021
Martin Emerson	Director	12/08/2021
Brendan Case	Company Secretary

Date of first appointment, title may have changed.

Directors & Executives (former)

NAME	TITLE	DATE OF APPOINTMENT	DATE OF RESIGNATION

Date of first appointment, title may have changed.